Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1915.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1994.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1170.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1355.0,1.0,=,0.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,672.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,729.0,1.0,=,0.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,571.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,841.0,1.0,=,0.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3338.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,3099.0,1.0,=,1.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3486.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,3181.0,1.0,=,1.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2294.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2257.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,697.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,615.0,1.0,=,1.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2572.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2026.0,1.0,=,1.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,939.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,925.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1445.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1717.0,1.0,=,0.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2205.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2069.0,1.0,=,1.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1689.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1259.0,1.0,=,1.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3189.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,2676.0,1.0,=,1.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1352.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1720.0,1.0,=,0.8